
## **Diamantis Plachouras**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2221073/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mortality review as a tool to assess the contribution of healthcare-associated infections to death: results of a multicentre validity and reproducibility study, 11 European Union countries, 2017 to 2018. Eurosurveillance, 2021, 26, .	3.9	3
2	The health and economic burden of antimicrobial resistance. , 2020, , 23-44.		2
3	Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019. Eurosurveillance, 2020, 25, .	3.9	28
4	A governance framework for development and assessment of national action plans on antimicrobial resistance. Lancet Infectious Diseases, The, 2019, 19, e371-e384.	4.6	62
5	Burden of healthcare-associated infections in European acute care hospitals. Wiener Medizinische Wochenschrift, 2019, 169, 3-5.	0.5	32
6	Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infectious Diseases, The, 2019, 19, 56-66.	4.6	1,908
7	Application of a new methodology and R package reveals a high burden of healthcare-associated infections (HAI) in Germany compared to the average in the European Union/European Economic Area, 2011 to 2012. Eurosurveillance, 2019, 24, .	3.9	20
8	Healthcare-associated pneumonia in acute care hospitals in European Union/European Economic Area countries: an analysis of data from a point prevalence survey, 2011 to 2012. Eurosurveillance, 2018, 23, .	3.9	48
9	ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units. Intensive Care Medicine, 2018, 44, 2216-2218.	3.9	50
10	Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi50-vi58.	1.3	89
11	Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi30-vi39.	1.3	43
12	Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi40-vi49.	1.3	61
13	Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi59-vi66.	1.3	30
14	Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Eurosurveillance, 2018, 23, .	3.9	62
15	Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Eurosurveillance, 2018, 23, .	3.9	392
16	Antimicrobial stewardship: we know it works; time to make sure it is in place everywhere. , 2017, 2, ED000119.		13
17	Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Medicine, 2016, 13, e1002150.	3.9	436
18	A Concise Set of Structure and Process Indicators to Assess and Compare Antimicrobial Stewardship Programs Among EU and US Hospitals: Results From a Multinational Expert Panel. Infection Control and Hospital Epidemiology, 2016, 37, 1201-1211.	1.0	35

#	Article	IF	CITATIONS
19	Planet's population on the move, infections on the rise. Intensive Care Medicine, 2016, 42, 2055-2058.	3.9	10
20	Impact of patients' professional and educational status on perception of an antibiotic policy campaign: a pilot study at a university hospital. Journal of Global Antimicrobial Resistance, 2016, 6, 123-127.	0.9	11
21	Spatiotemporal Evolution of Ebola Virus Disease at Sub-National Level during the 2014 West Africa Epidemic: Model Scrutiny and Data Meagreness. PLoS ONE, 2016, 11, e0147172.	1.1	32
22	Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. Eurosurveillance, 2016, 21, .	3.9	109
23	Mycobacterium chimaera infections associated with heater-cooler units (HCU): closing another loophole in patient safety. Eurosurveillance, 2016, 21, .	3.9	18
24	Risk factors for community-associated methicillin-resistant Staphylococcus aureus colonisation in a large metropolitan area in Greece: An epidemiological study using two case definitions. Journal of Global Antimicrobial Resistance, 2014, 2, 27-33.	0.9	4
25	Promoting prudent use of antibiotics: the experience from a multifaceted regional campaign in Greece. BMC Public Health, 2014, 14, 866.	1.2	23
26	Primary Polydipsia. Journal of Nervous and Mental Disease, 2013, 201, 709-711.	0.5	5
27	Antimicrobial activity of copper surfaces against carbapenemase-producing contemporary Gram-negative clinical isolates. Journal of Antimicrobial Chemotherapy, 2013, 68, 852-857.	1.3	49
28	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2013, 57, 668-671.	1.4	71
29	A crossed brain stem syndrome without crossed sensory symptomatology. BMJ Case Reports, 2013, 2013, bcr2012006709-bcr2012006709.	0.2	4
30	Genetic polymorphisms within tumor necrosis factor gene promoter region: A role for susceptibility to ventilator-associated pneumonia. Cytokine, 2012, 59, 358-363.	1.4	20
31	Application of a Loading Dose of Colistin Methanesulfonate in Critically III Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 2012, 56, 4241-4249.	1.4	201
32	Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2011, 37, 187-193.	1.1	64
33	Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clinical Microbiology and Infection, 2011, 17, E9-E11.	2.8	86
34	Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infectious Diseases, 2010, 10, 286.	1.3	22
35	Serum and Cerebrospinal Fluid Levels of Colistin in Pediatric Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 3985-3987.	1.4	61
36	Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Critical Care, 2010, 14, R96.	2.5	109

DIAMANTIS PLACHOURAS

#	Article	IF	CITATIONS
37	Efficacy and Tolerability of Linezolid in Chronic Osteomyelitis and Prosthetic Joint Infections: A Case-Control Study. Journal of Chemotherapy, 2009, 21, 165-169.	0.7	18
38	Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infectious Diseases, 2009, 9, 213.	1.3	47
39	Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 760-767.	1.4	94
40	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically III Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3430-3436.	1.4	448
41	Does a bed rail system of alcohol-based handrub antiseptic improve compliance of health care workers with hand hygiene? Results from a pilot study. American Journal of Infection Control, 2009, 37, 160-163.	1.1	17
42	In vitro elution of moxifloxacin and fusidic acid by a synthetic crystallic semihydrate form of calcium sulphate (Stimulanâ"¢). International Journal of Antimicrobial Agents, 2008, 32, 485-487.	1.1	21
43	Evaluation of different laboratory tests for the detection of metallo-Â-lactamase production in Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2008, 61, 548-553.	1.3	107
44	Effect of Clarithromycin in Patients with Sepsis and Ventilatorâ€Associated Pneumonia. Clinical Infectious Diseases, 2008, 46, 1157-1164.	2.9	227
45	In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2007, 57, 419-422.	0.8	32
46	Monocytes as a site of production of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in the septic host. Scandinavian Journal of Infectious Diseases, 2006, 38, 909-915.	1.5	3
47	Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. Critical Care, 2006, 10, R76.	2.5	47
48	Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Critical Care, 2006, 10, R166.	2.5	67
49	Portal and Systemic Endotoxemia in Abdominal Operations: The Significance of Acute Abdomen. Journal of Surgical Research, 2006, 134, 133-137.	0.8	7
50	No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment. Clinical Infectious Diseases, 2006, 43, e89-e91.	2.9	26
51	Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scandinavian Journal of Infectious Diseases, 2005, 37, 48-54.	1.5	24
52	Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2005, 51, 113-117.	0.8	23
53	Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clinical and Experimental Immunology, 2004, 135, 240-246.	1.1	41
54	Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clinical Microbiology and Infection, 2004, 10, 628-633.	2.8	76

#	Article	IF	CITATIONS
55	Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2003, 51, 423-426.	1.3	4